Results 91 to 100 of about 13,963,189 (308)

Therapy and Outcomes of Patients with Relapsed Nonmetastatic Rhabdomyosarcoma: A Report from the French Society of Pediatric Oncology Malignant Mesenchymal Tumor Committee

Cancer Medicine
Background The prognosis for patients with relapse of localized rhabdomyosarcoma (RMS) remains poor, with limited evidence for optimal second‐line therapy. This study describes the management and outcomes of relapsed RMS patients in France.
François Sevrin, Emilie Bogart, Daniel Orbach, Marie Cécile Le Deley, Pablo Berlanga, Valérie Bernier, Nadège Corradini, Cindy Fayard, Florent Guerin, Sarah Jannier, Marie Karanian, Stéphanie Proust, Angélique Rome, Cécile Verité, Véronique Minard‐Colin, Anne‐Sophie Defachelles   +15 more
doaj   +1 more source

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

, 2017
Divaya Bhutani, Jeffrey A Zonder Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in ...
Zonder JA, Bhutani D
core  

Efficacy of gemcitabine as second-line therapy after S-1 therapy failure in advanced pancreatic carcinoma.

, 2012
248 Background: Gemcitabine (GEM) and GEM-containing combination chemotherapy have been established as standard first-line therapies for advanced pancreatic carcinoma (APC).
Masaru Fukahori
core   +1 more source

Supplementary Figure 1. Kaplan-Meier analysis of overall survival by line of therapy

, 2021
Supplementary Figure 1. Kaplan-Meier analysis of overall survival by line of therapy. (A) First-line therapy, (B) second-line therapy, (C) third-line therapy and (D) fourth-line therapy.Treatment patterns and overall survival in HER2-positive metastatic
Santosh Gautam (11675020), Maxine D Fisher (11675021), Kendra DeBusk (5198249), Sonia Pulgar (625631), Gregory A Vidal (11675019), Anna Vlahiotis (9240688)   +5 more
core   +1 more source

Smaller is better: nanobodies meet NMR

FEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

Neutralization of the PTX3/CD44 axis suppresses TGF‐β1 signaling in kidney fibrosis

FEBS Letters, EarlyView.
This study investigates how the PTX3/CD44 axis promotes kidney fibrosis by activating TGF‐β1 signaling. We demonstrate that the neutralizing antibody WHC‐001 effectively inhibits this pathway, suppressing myofibroblast activation and partial epithelial–mesenchymal transition (EMT).
Chao‐Chun Cheng, Shen‐Shin Chang, Feng‐Wei Chen, Ying‐Chieh Su, Thanh Phuong Nguyen, Yu‐Wei Hsiao, Jhih‐Ying Chi, Hsin‐Yin Liang, Ju‐Ming Wang   +8 more
wiley   +1 more source

First line catecholamine therapy for vasoplegia A (left) and second line catecholamine choice in percent B (right).

, 2014
First line catecholamine therapy for vasoplegia A (left) and second line catecholamine choice in percent B (right).
Konrad Reinhart (51097), Sebastian N. Stehr (607462), Uwe Schirmer (607461), Christoph Schelenz (607460), Christoph Sponholz (124222)   +4 more
core   +1 more source

Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa [PDF]

, 2014
BACKGROUND There is debate over using tenofovir or zidovudine alongside lamivudine in second-line antiretroviral therapy (ART) following stavudine failure.
Orrell, Catherine, Egger, Matthias, Gerber, Florian, Zwahlen, Marcel, Hoffmann, Christopher J, Gsponer, Thomas, Chimbetete, Cleophas, Wandeler, Gilles, Chi, Benjamin H, Prozesky, Hans, Boulle, Andrew, Rohr, Julia, Fox, Matthew P, Africa, Iedea Southern, Egger M, Orrell C, Wandeler G, Chimbetete C, Hoffmann CJ, Chi BH, Gerber F, Gsponer T, Rohr J, Zwahlen M, Boulle A, Fox MP, Prozesky H   +26 more
core   +3 more sources

Inhibition of dipeptidyl peptidase 7 impairs lysophagy in LLOMe‐treated HepG2 cells

FEBS Letters, EarlyView.
DPP7 inhibition delays ubiquitin‐dependent lysophagy by attenuating ubiquitin accumulation and the recruitment of SQSTM1 and LC3 to damaged lysosomes, resulting in delayed clearance of damaged lysosomes and impaired restoration of lysosomal homeostasis. Created using FigureLabs (Certificate ID: FL‐PUB‐20260922‐Z99XNX).
Na Yeon Park, Inho Kwon, Yong Hwan Kim, Ji‐Eun Bae, Joon Bum Kim, Seong Hyun Kim, Sungho Maeng, Doo Sin Jo, Dong‐Hyung Cho   +8 more
wiley   +1 more source

A Randomized, Prospective and Crossover Study, Comparing the Eradication Rate After 10 Days of Concomitant Therapy to Bismuth Quadruple Therapy Among a Sample of the Lebanese Population

Current Therapeutic Research
: Background: Concomitant therapy and bismuth quadruple therapy are both recommended as first-line treatment regimens for the empiric treatment of Helicobacter pylori infection, especially after the increased resistance to clarithromycin. Objective: Our
Jad Chidiac, MD, Reine-Marie Kahwaji, MD, Souheil Hallit, PharmD, MSc, MPH, PhD, Yara Yazbeck, MD, Bassem Akiki, MD, Charbel Yazbeck, MD   +5 more
doaj   +1 more source